報價延遲最少15分鐘:2026/02/09 19:06 EST
盤後時段
|
||||
|
12.02 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.02
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.50/4.05
|
|
企業價值
121.52M
|
| 資產負債 |
|
每股賬面淨值
16.49
|
| 現金流量 |
|
現金流量率
0.16
|
| 損益表 |
|
收益
700.00K
|
|
每股收益
26.18
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild tomoderate pain. |
